Microglial cells, the resident immune cells of the spinal cord, become activated in response to peripheral nerve injury. Microglia activation contributes to the development of neuropathic pain. Here we employed microarray analysis of individually collected pools of 10 spinal microglia cells to identify changes of levels and cell-to-cell expression variance of microglial genes during their activation after peripheral nerve injury. The analysis of microglia on postoperative day 1 (POD1) identified miR-29c as a critical factor for microglial activation and the development of neuropathic pain. Early POD1 microglia exhibited a very distinct expression profile compared to late POD7 microglia, possibly leading to the transition from initiation to maintenance of neuropathic pain. We found sample variance patterns that were consistent with the hypothesis that microglia were highly heterogeneous at the level of individual cells, and variation analysis identified 56 microglial genes potentially linked to the maintenance of neuropathic pain which included Gria1. This study provides insights into spinal microglial biology and reveals novel microglial targets for the treatment of neuropathic pain.
Introduction
Chronic pain is a main public medical issue that undermines the quality of life, especially because of the current lack of effective therapies controlling pain in patients. 12, 15 Neuropathic pain is the most difficult form of chronic pain and sciatic nerve injury in rodents leads to persistent tactile allodynia in which innocuous stimuli elicit abnormal pain hypersensitivity and spontaneous pain, 2 main symptoms of neuropathic pain. 7 Interestingly, neuropathic pain is regulated by immune reactions in the spinal cord, which are mediated by resident microglia, astrocytes, and infiltrating immune cells. 20, 42, 47 Microglia are resident immune cells of the central nervous system (CNS) which participate both in maintaining homeostasis and in sensing pathological changes. 48 In response to peripheral nerve injury, spinal microglia become activated through a progressive series of cellular and molecular changes. 6, 23 Activated microglia in spinal dorsal horns contribute to central sensitization, the key mechanism for the development of neuropathic pain. 18, 24, 57 Despite recent progress in our understanding of microglial biology 5, 9, 26 and identification of several microglial factors which contribute to neuropathic pain, 10, 54, 55 the molecular mechanisms by which resting microglia are switched to activated forms after nerve injury have not yet fully understood. Given the poor efficacy of current drugs targeting neuronal activity in neuropathic pain, 20 identifying microglial factors could be important for unraveling the molecular mechanisms and finding novel targets. Cellular phenotypes are determined by multiple processes involving gene and protein expression. 58 Large-scale screening for pain-related genes on spinal cord or dorsal root ganglia (DRG) has revealed substantial expressional changes in hundreds of genes. 11, 36, 51 However, most of these genes are neuronal not microglial, indicating that whole tissue analysis may have limitations in finding targets from the spinal microglia whose transcriptome is expected to be a minor fraction of whole tissue transcriptome. Single-cell transcriptome analysis has revealed cell-to-cell variations in the same tissue which were masked at the whole tissue level. 16, 49 These studies have suggested that an alternative approach for identifying microglial targets is to perform expression profiling at higher resolution which allows us to identify rare transcripts and screen for effects on cell-to-cell variability.
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In this study, we employed near single-cell microarray analysis of microglia from spinal cord slices after L4 spinal nerve transection (SNT). Recent researchers have achieved single-cell resolution for the whole transcriptome 35 but given the size of the microglia, we collected pools of 10 cells. Although the collection of 10 cells is not at the level of single cells, mechanical selection of individual cells helped to generate microglia-enriched samples. Using this approach, we investigated a murine microglial transcriptome between nerve-injured vs sham-operated microglia at POD1 and POD7. By comparing gene profiles between these 2 time points, we aimed to identify novel genes exclusively involved in microglia activation after nerve injury, which may lead to initiation of neuropathic pain and to find novel microglial genes specifically involved in the transition to neuropathic pain development and/or maintenance.
Materials and methods

Mice
Adult C57BL/6 and heterozygous Cx3cr1 1/GFP male mice (8-10 weeks old) produced by breeding Cx3cr1GFP/GFP mice 30 with wild type C57BL/6 were used for this work. Five mice per cage were kept. All animals were housed on a 12 hour/12 hour light/ dark cycle with food and water provided ad libitum. Mice were acclimatized for at least one week before the experiments.
Animal models
All surgical and experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the School of Dentistry, Seoul National University before the experiments. Animal treatments were performed according to the Guidelines of the International Association for the Study of Pain. For the spinal nerve transection model, the surgery was performed as described previously. 13, 32 Briefly, under sodium pentobarbital anesthesia, a 1 cm longitudinal incision overlying the L3-L6 section was made. The right paraspinal muscles were separated from the superior articular processes and the transverse processes to expose the L3 and L4 spinal nerves. The L4 spinal nerve was transected without damaging the L3 spinal nerve. The wound was closed by suturing the muscle and skin layers. The sham group received a sham surgery without nerve transection.
Behavioral test
Mechanical sensitivity was assessed at 1-day and 7-day after nerve injury during daytime by the up-down method using calibrated von Frey filaments as described previously. 8 Six mice for each group were tested. Mice were acclimatized on a metal mesh floor in transparent plastic boxes (60 3 100 3 60 mm) for 1 hour. The mechanical sensitivity was evaluated using a set of 8 calibrated von Frey filaments (0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1.0, and 1.4 g; Stoelting, Wood Dale, IL) that were applied to the plantar surface of the hind paw until the filament bent slightly for a few seconds. A withdrawal reflex of the hind paw during stimulation or immediately after stimulus removal was considered a positive response. The first stimulus was always the 0.4 g filament. When there was a positive response, the next lower filament was applied, and when there was no response, the next higher filament was used. After the first change in responses, 4 additional responses were observed and the 50% paw withdrawal threshold value was calculated.
14 Sensory motor coordination was examined by using the rotarod test. All behavioral tests were performed blindly.
Microglial cell collection
Mice were deeply anesthetized with excess isoflurane and decapitated. The spinal cord including the lumbosacral enlargement (L3-L5) was exposed by a dorsal laminectomy. Dissected tissue blocks were placed into ice-cold cutting solution containing (in millimolars) 245 sucrose, 3 KCl, 6.0 MgCl 2 , 0.5 CaCl 2 , 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 11 glucose, 5 N- [2-hydroxyethyl] piperazine-N9-[2-ethanesulfonic acid] (HEPES), 1.0 Kynurenic acid (pH 7.4, when bubbled with 95% O 2 /5% CO 2 ). Transverse slices (300 mm) were prepared using vibroslicer (Lieca VT1000 Plus; Leica Microsystems GmbH, Wetzlar, Germany) and collected in a slice chamber containing recording artificial cerebrospinal fluid (aCSF) composed of (in millimolars) 126 NaCl, 3 KCl, 1.3 MgCl 2 , 2.5 CaCl 2 , 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 11 glucose, and 5 HEPES (pH 7.4, when bubbled with 95% O 2 and 5% CO 2 and had osmolarity of 305-310 mOsmol). The slices were initially maintained at 32˚C for 45 minutes to recover and transferred to the slice chamber kept at room temperature (25 6 1˚C) until used. Slices were continuously superfused with diethylpyrocarbonate (DEPC)-treated aCSF (;5 mL per minute). Individual cell collection was performed as previously described. 33 Briefly, CX3CR1-enhanced green fluorescent protein-positive microglia located approximately 30 to 60 mm underneath the superficial dorsal horn (laminae I and II) was visualized under fluorescence microscopy. Individual spinal microglia from 3 different spinal cord slices were randomly collected with approximately 10-mm glass pipettes gently put into a reaction tube containing reverse transcription reagents. Individually identified microglia forming samples of 10 cells were used for each microarray transcriptome assay. Each sample represents an average of 10 cells and although the measurement is not at the single-cell level, the sample-to-sample variation is expected to be proportional to the single cell variation. If the variance among single cells is v, then by assuming a random pool of 10 cells, the variance of the 10-cell averages is expected to be proportional to v/10. The cDNA was synthesized from 10 pooled microglia collected from three spinal cord slices obtained from one animal, and it was used for each microarray chip. Ten microglia were selected 6 times for each experimental group which consists of 6 mice. A total of 24 mice were tested.
RNA isolation and microarray expression profiling
Microarray samples were prepared as described previously. 17 Briefly, the total RNA from 10 pooled microglia was reversetranscribed into cDNA using a SMART er Pico PCR cDNA Synthesis Kit (Takara Clontech, Kyoto, Japan). Advantage2 Polymerase Mix (Takara Clontech) was used to amplify the whole cDNA according to the manufacturer's instructions. The reaction profile was 1 minute at 95˚C; 20 cycles of 5 seconds at 95˚C, 5 seconds at 65˚C, or 6 minutes at 68˚C. We then added 2 mL of 12 mM modified Primer IIA with the T7 promoter and 2 mL of 503 Advantage2 Polymerase Mix again and performed another thermal cycling for 1 minute at 95˚C, 10 cycles of 5 seconds at 95˚C, 5 seconds at 65˚C, 6 minutes at 68˚C, or 6 minutes at 68˚C. To assess the quality of cDNA prepared from 10 pooled cells for microarray experiment, a portion of the cDNA (1 mL) was used as a template for nested polymerase chain reaction (PCR) to detect b-actin and CD11b expression. Aspirated bath solution was used as the negative control. All PCR amplifications were performed with nested primers. The sequence used are as follows: CD11b, 59-ACATGT-GAG CCCCATAAAGC-39 and 59-TCAGGGCTTCAAAGTTGTCC-39 in the first PCR (326 bp), 59-ACATGTGAGCCCCATAAAGC-39 and 59-AATGACCCCTGCTCTGTCTG-39 in the second nested PCR (205 bp); b-actin, 59-CATCACTATTGGCAACGAGCG-39 and  59-ACATCTGCTGGAAGGTGGACAG-39 in the first PCR (325 bp),  59-GGCTCTTTTCCAGCCTTCCTT-39 and 59-CCACCGATCCA-CACAGAGTACT-39 in the second nested PCR (251 bp) .
With samples verified with reverse transcription polymerase chain reaction (RT-PCR), 3.4 mg per cDNA sample was used as input into the Affymetrix procedure as recommended by protocol. Amplified RNA (cRNA) was generated from the double-stranded cDNA template through an in vitro transcription (IVT) reaction and purified with the Affymetrix sample cleanup module. The cDNA was regenerated through a random-primed reverse transcription using a dNTP mix containing dUTP. The cDNA was then fragmented by UDG and APE 1 restriction endonucleases and end-labeled by a terminal transferase reaction incorporating a biotinylated dideoxynucleotide. Fragmented end-labeled cDNA was hybridized to the Affymetrix GeneChip Mouse Gene 1.0 ST arrays for 16 hours at 45˚C and 60 rpm as described in the Gene Chip Whole Transcript Sense Target Labeling Assay Manual (Affymetrix, Santa Clara, CA). After hybridization, the chips were stained and washed in a Genechip Fluidics Station 450 (Affymetrix) and scanned by using a Genechip Array scanner 3000 7G (Affymetrix). Six biologically independent hybridizations were performed for each condition. The raw data for individual plates (libraries) are accessible in Gene Expression Omnibus under the accession code GSE60670.
Microarray data processing
The image data were extracted through Affymetrix Command Console Software 1.1. The raw .cel file generated through the abovementioned procedure meant expression intensity data and was used for the next step. Expression data were generated by Affymetrix Expression Console Software version 1.1. Global gene expression profiles and single cell variation analysis were performed. Six biologically independent hybridizations were performed for each experimental group excluding the shamPOD1 group (n 5 5 for shamPOD1 group). We excluded one of "shamPOD1" sample from the 6 shamPOD1 samples because it turned out that the shamPOD1 sample was an outlier according to the Spearman's correlation coefficients analysis.
We normalized the arrays using Robust Multichip Average (RMA) normalization. 28 In order to obtain robust expression values from 10-cell samples, we summarized perfect match probes on the array by specifically taking the log of the second highest perfect match probe intensity. In addition, we removed batch effects using a 2-stage least squares method for estimation of location and scale parameters because nonbiological variability, such as differences in sample preparation and hybridization protocols, can be potentially confounding biological differences. 19 For differential expression analysis, a t test was performed. To compare the distribution of coefficient of variation (CV) between conditions, Wilcoxon rank-sum test was conducted. For heat maps, we used following web site; http://www.tm4.org/mev.html.
Metric multidimensional scaling (MDS) was performed to visualize the heterogeneity of gene expression profile between any pair of samples. Briefly, metric MDS finds an orthogonal projection to a set of axes ordered by the amount of variance. In addition, we applied a linear discriminant analysis (LDA) analysis to investigate whether different classes have distinct patterns where the axes were rescaled to make the 2 sets of projects comparable. Linear discriminant analysis finds a linear function of the variables that maximizes the ratio of between-class variance and minimizes the ratio of within-class variance. Metric multidimensional scaling and LDA were performed using an implementation in the R Statistical Software package downloaded from www.r-project.org.
To assess within-group similarity of gene expression, we used the symmetric Jensen-Shannon divergence (JSD) index, which ranges from 0 (identical) to 1 ("distant" distributions) such that lower JSD scores reflect higher similarity between transcriptomes. To measure cell-to-cell variability captured in 10-cell units, we used the CV defined by the ratio of the SD to the mean (CV 5 SD/mean). The variances between groups were assessed using an equality of variances F test. A 2-sample F test was performed to compare 2 population variances.
Functional and pathway analysis
To understand molecular functions involved in the early and late microglia, each of the POD1-specific, POD7-specific, and common differentially expressed genes (DEGs) were input to Pathway Studio (version 9.0; Ariadne Genomics, Rockville, MD) 43 and Gene Ontology (GO) classification was performed. Gene set enrichment analysis was applied to search for groups of genes involved in the same processes (gene sets) that were altered significantly by nerve injury. Cutoff parameters for significance were P value ,0.01 and overlap (the number of overapped genes) .2. We analyzed disease pathways using Pathway Studio. Disease entities were identified using the "common targets" option.
Primary microglia culture
Mixed glial cultures were prepared from cerebral cortex of 1 to 2-day-old postnatal mice in accordance with the method described previously. 2 Briefly, mixed glial cells were cultured and maintained for 14 to 16 days in high-glucose DMEM medium including 10% fetal bovine serum. Microglia were harvested from the mixed glia by shaking T75 flasks. The media including floating cells were collected and microglia were plated onto 6-well plates in the density of 1.0 3 10 6 cells per milliliter for subsequent ATP treatments or used for transfection. Microglia purity was greater than 95%, as confirmed by Iba1 staining. Two days after plating, microglia were treated with 50 mM ATP (Sigma, St. Louis, MO) for 1 hour which was previously shown to activate microglia. 54 
Quantitative real-time reverse transcription polymerase chain reaction
Total RNA or specifically the small RNA fraction was extracted by using an RNeasy Mini Kit or miRNeasy Mini kit (Qiagen, Valencia, CA) respectively, and 0.5 to 1.0 mg was processed for cDNA synthesis using M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA) or miScript PCR Starter Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The primers used for miRNA were miR29b-3p, 59-UAGCACCAUUUGAAAUCAGUGUU-39 (cat no. MS00005936, miScript Primer Assays); miR-29c-3p, 59-UAGCAC-CAUUUGAAAUCGGUUA-39 (cat no. MS00001379, miScript Primer Assays); miR-137-3p, and 59-UUAUUGCUUAA-GAAUACGCGUAG-39 (cat no. MS00001589, miScript Primer Assays); snRNA RNU6B (RNU6-2), which were provided in a miScript PCR Starter Kit (cat no. MS00033740; miScript Primer Assays). Real-time PCR was performed with cDNA prepared for microarray experiments or obtained from primary cultured microglia as a template using a 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). The threshold cycle (Ct) of the GAPDH or snRNA RNU6B was used as a reference control to normalize the expression level of the target gene (DCt) to correct for experimental variation. Relative mRNA levels were calculated according to the 2-DDCt method. 39 Real 
Western blotting
Proteins were prepared using Pro-Prep solution (Intron biotechnology, Seoul, Korea). Protein concentration was determined using a BCA assay kit (Pierce, Rockford, IL). Thirty micrograms of proteins were separated by 10% SDS-PAGE electrophoresis and transferred onto a PVDF membrane. After blocking, the membrane was probed with anti-pp38 (Cell Signaling Technology, Beverly, MA, cat no. 4631s, 1:1000) and p38 (Cell Signaling Technology, cat no. 9212, 1:1000) overnight followed by horseradish peroxidase-conjugated antirabbit (Santa Cruz Biotechnology, Santa Cruz, CA, cat no. sc2004, 1:5000) for 1 hour at room temperature. Blots were detected and quantified using a Gel-Doc XRS1 system (BioRad, Hercules, CA) by using a chemiluminescent reagent (SuperSignal West Pico; Thermo Fisher Scientific, Waltham, MA). Independent experiments were conducted at least 3 times. To increase miR-29c levels, we administered a chemically modified double-stranded miRNA mimic. Primary cultured microglia were transfected with Gria1 siRNA (10 nM) or miR-29c inhibitor (10 nM) or miR-29c mimic (10 nM) by electroporation using a microporator (MP-100; Digital Bio Technology Co., Seoul, Korea) following the manufacturer's instructions. Transfected microglia was seeded at 1 3 10 6 cells per well of 6-well plates. Real-time PCR was used to determine knockdown efficacy of siRNA, miRNA inhibitor, and miR-29c mimic. After 48 hours for Gria1 and miR-29c mimic and 60 hours for miR-29c inhibitor, we harvested the transfected microglia and, after centrifugation, transferred only microglial cell resuspended in PBS, without culture media, into animals.
Intrathecal injection of microglia and drug injection
Gria1 knockdown microglia or miR-29c inhibited microglia (1 3 10 6 cells, 10 mL) were injected intrathecally in normal mice as described previously. 27 Briefly, under isoflurane anesthesia, mice were injected using a 50 mL Hamilton syringe fitted with a 31 gauge needle by direct lumbar puncture between the L5 and L6 levels. Control animals were injected with microglia transfected with the NC5 negative control (miRNA inhibitor control, NC) or the negative control siRNA (siScram). Paw withdrawal threshold was tested 1, 3, and 5 hours after injection.
The TNFa antagonist etanercept (25 mg per vial; Enbrel, Wyeth, Taplow, Maidenhead, United Kingdom) was administrated by systemic intraperitoneal injection 1 hour after microglial injection. Dilution before administrations was made in PBS for treatment of mice.
Preparation of DRG neurons
Dorsal root ganglia neurons obtained from 4 to 6-week-old mice were prepared. Animals were anesthetized with overdose of isoflurane, decapitated, and DRG were rapidly removed under aseptic conditions and placed in HBSS (Gibco, Gaithersburg, MD). Dorsal root ganglia were digested in 1 mg/mL collagenase A (Roche, Mannheim, Germany) and in 2.4 U/mL dispase II (Roche) in HBSS for 60 minutes, respectively, followed by 8 minutes in 0.25% trypsin (Sigma), all at 37˚C. The DRG were then washed in neurobasal medium (Gibco) 3 times and resuspended in DMEM medium supplemented with 10% FBS (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin (Sigma). They were then mechanically dissociated using fire-polished glass pipettes, centrifuged (800 rpm, 5 minutes), and resuspended in DMEM medium supplemented with 10% FBS (Invitrogen), 13 B-27 supplement (Invitrogen), 13 N-2 supplement (Invitrogen), and 1% penicillin/ streptomycin (Invitrogen), and plated on 0.5 mg/mL poly-D-lysine (Sigma)-coated glass coverslips. Cells were maintained at 37˚C in a 5% CO 2 incubator.
Ca 21 imaging
We performed fura-2 AM-based (Molecular Probes, Eugene, OR) Ca 21 imaging experiments. The DRG neurons were loaded with fura-2 AM (2 mM) for 40 minutes at 37˚C in a balanced salt solution containing (in millimolars) 140 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, 10 glucose, adjusted to pH 7.3 with NaOH. The cells were then rinsed with the Neurobasal medium and incubated in it for an additional 20 minutes to deesterify the dye. Cells on slides were placed onto an inverted microscope and illuminated with a 175 W xenon arc lamp; excitation wavelengths (340/380 nm) were selected by a monochromator wavelength changer. Electrical stimuli (0.01 millisecond, 0.0167 Hz) were delivered through a theta glass suction electrode, which was filled with aCSF and placed in the dorsal root. After a baseline recording (10 minutes), the microglial cells (1 3 10 6 in 500 mL) were focally perfused into spinal dorsal horn through a borosilicate capillary placed toward the recording area. The amplitude of evoked fPSPs was measured, 2 consecutive fPSP were averaged, and these measurements were expressed relative to the normalized baseline.
Immunofluorescence
After fixing microglia with 4% paraformaldehyde for 10 minutes at room temperature, microglia were incubated for 1 hour in a blocking solution containing 5% normal donkey serum (Jackson ImmunoResearch Laboratories, Bar Harbor, ME) and 5% FBS (Gibco) in PBS-T (0.1% Triton X-100). The cells were incubated with primary antibody for rabbit anti-GluA1 (1: 500; Millipore, cat no. AB1504) and rabbit anti-Iba1 (1:1000; Wako, Tokyo, Japan, cat no. 019-1974) at 4˚C overnight. After rinsing with PBS, the cells were incubated with Alexa fluor 488 goat antirabbit (1:200; Jackson ImmunoResearch Laboratories) and cy3 fluor goat antirabbit (1:200; Jackson ImmunoResearch Laboratories) at room temperature for 1 hour. Following washing with PBS, cells were mounted with the Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Fluorescent images were obtained using a confocal microscope (LSM700; Carl Zeiss, Germany). Independent experiments were performed at least 3 times.
Enzyme-linked immunosorbent assay (ELISA)
After transfection, primary cultured microglia were plated 1.5 3 10 6 cells per well in 6-well plates and cell supernatants were collected 48 hours after transfection. The levels of TNFa in supernatants were quantified using the mouse TNFa Duoset ELISA kit (R&D Systems, Minneapolis, MN, cat no. DY410-05). For each reaction in a 96-well plate, 100 mL of supernatants were used, and ELISA was performed according to the manufacturer's instructions. Independent experiments were performed 3 times.
In situ hybridization of miR-29c
In situ hybridizations were performed in 14-mm cryosections from spinal cord. Sections were fixed in 4% paraformaldehyde-0.1 M PBS for 30 minutes followed by washes in diethylpyrocarbonatetreated ultrapure water. After treatment with a mixture of 30% H 2 O 2 and methanol (v/v 5 1:50) for 30 minutes, the sections were treated with proteinase K (Boster, China) for 2 minutes at room temperature. The sections were prehybridized in a hybridization solution (50% deionised formamide, 0.3 M NaCl, 5 mM EDTA, 10 mM NaPO 4 , 0.5 mg/mL yeast tRNA, 10% dextran Sulfate, and 13 denhardt's solution) at 25˚C below the predicted Tm value of the LNA probe for 2 hours. Next, sections were incubated with 59-DIG-labeled and 39-DIG-labeled mature miR-29c miRCURY LNA detection probe (/5DigN/TAA CCG ATT TCA AAT GGT GCT A/ 3Dig_N/) or microRNA detection control probes for ISH (/5DigN/ GTG TAA CAC GTC TAT ACG CCC A/3Dig_N/) (Exiqon, Vedbaek, Denmark) at 53˚C overnight. Sections were then incubated in blocking solution at 37˚C for 30 minutes and in mouse anti-DIG-biotin for 60 minutes, washed, and incubated using an SABC-FITC regent (Boster) for 30 minutes. To identify the cell types expressing miR-29c, the above sections under ISH were incubated overnight at 4˚C with primary antibodies against GFAP (mouse, 1:6000; Millipore), NeuN (mouse, 1:1000; Millipore), or IBA-1 (rabbit, 1:3000; Wako). On the following day, Cy3-conjugated secondary antibody was added and incubated for 2 hours. The signal was detected with a Leica fluorescence microscope, and images were captured with a CCD Spot camera.
Statistics
All data were checked for normality (Shapiro Wilk) before statistical testing. For the data showing nonnormal distribution, we performed Mann-Whitney U test. Data were presented as mean 6 SEM and were analyzed using SPSS and GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). For sample sizes, no statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in this field. Statistical analyses of the 50% withdrawal thresholds were performed using the Mann-Whitney U test at individual time points or 2-way repeated ANOVA. The unpaired 2-tailed Student t test was used for real-time PCR analysis, western blotting, and calcium imaging analysis. The value of P , 0.05 was considered statistically significant.
Results
Validation of 10-cell microarray data
L4 spinal nerve transection produced significant mechanical allodynia from POD1 and peaked at POD7 (Fig. 1A) . Microglia in the ipsilateral dorsal horn largely consisted of activated microglia, which was identified by CX3CR1-enhanced green fluorescent protein-positive expression (Fig. 1B) . We selected these 2 time points, POD1 and POD7 to compare microglial gene profiles during neuropathic pain initiation and development or maintenance against respective sham-operated controls (Fig. 1A) . Reverse transcription polymerase chain reaction revealed the expression of CD11b (Fig. 1D) in microglia randomly collected with glass pipettes from superficial laminae of L3 to L5 spinal dorsal horn (Fig. 1C) , but not in negative controls consisting of aspirates of the bath solution (Fig. 1D) , indicating there were no detectable levels of RNA contamination.
To check the consistency of 10-cell microarray data, 14 microglial genes previously known to increase their expression after nerve injury and closely associated with neuropathic pain 21, 52, 55, 59 were examined ( Fig. 2A) . Most of the 14 genes were upregulated after injury. In contrast, housekeeping genes and most marker genes for other CNS cell types showed insignificant changes (Figs. 2A, E) . We further validated the data with real-time PCR by confirming increased expression of randomly selected 5 genes among the 14 microglial genes (Fig.  2D) . We also examined the 29 spinal cord microglia-specific genes recently reported by Chiu et al. (Fig. 2B) . 9 We found that 28 genes (except one gene missing on our microarray chip) were highly expressed both in sham and injured microglia (Fig. 2B and Fig. S1A ; http://links.lww.com/PAIN/A202). Butovsky et al. reported 40 microglial genes that were uniquely expressed in central microglia but not in peripheral monocytes. 5 These 40 genes were also expressed both in sham and injured microglia (Fig. S1B) , and upregulated after nerve injury compared with their respective sham (Figs. 2C, E) . Taken together, these results demonstrate that the 14 previously known genes in 10-cell microarray results were consistent with expression profiles from previous studies and suitable for screening neuropathic pain-linked genes with minimal contamination from other CNS cell types.
Time-dependent differential changes in microglial gene expression after nerve injury
To find early and late responsive microglia genes for peripheral nerve injury, we determined DEGs by comparing the results from POD1 and POD7 with their respective sham-operated controls. A total of 559 genes whose expression significantly changed in microglia after nerve injury were identified. Of these, 312 genes were upregulated and 247 www.painjournalonline.comgenes were downregulated (Fig. 3A) . Of the 312 upregulated genes, 123 were significantly upregulated only at POD1 (POD1-specific DEG) and 167 were upregulated only at POD7 (POD7-specific DEG). The overlap between that obtained at POD1 and POD7 (common DEG) yielded 22 genes that were upregulated throughout the course of pain (Fig. 3B and Table. S1 ; http://links.lww.com/PAIN/A203). Interestingly, the POD1-specific DEGs included 3 miRNA genes such as miR-137, miR-29b-1, and miR-29c. Next, we analyzed DEGs using GO terms to assess whether certain functions or molecular pathways were significantly enriched within and across each time point. A number of genes related to chemotaxis, C5a signaling, succinate metabolic process, cytokine-mediated signaling, mitotic cell cycle, and cell shape were significantly enriched within the POD1 DEGs. For POD7, genes associated with Type I interferon mediated signaling, cellular response to calcium ion, cytokine-mediated signaling, interferon-g, chemotaxis, and phospholipid metabolic process were significantly regulated (Fig. 3C) . Gene functions involved in interleukin-6, chemokine, kinase, NF-kB, and toll-like receptor (TLR) signaling pathway were enriched in DEGs common to both time points (Fig. 3C) . Interestingly, early-phase and late-phase microglia were associated with distinct cellular compartments (Fig. 3D) . Genes associated with membrane, mitochondrial matrix, and nucleus changed at POD1, whereas genes located in the trans-Golgi transport vesicle, cytosol, and endoplasmic reticulum were largely altered at POD7. Plasma membrane-related genes were upregulated throughout the course of pain (Fig. 3D) . Although GO analysis is often weak, these results suggest that genes related to sensing function dominate at POD1 whereas expressions of genes induced by signaling pathways are more prevalent at POD7.
Identification of candidate pain-maintenance neuropathic microglial genes by variation analysis
We next investigated the sample-to-sample dispersion patterns to gain insights into potential single-cell variability of the microglia (we expected the 10-cell samples to reflect individual variability with a scaling factor of sqrt(n), n 5 10; see Methods). To visualize the dispersal patterns, metric MDS was performed. Visually, POD7 and shamPOD7 were more dispersed than POD1 and shamPOD1, respectively (Fig. 4A) . We also examined 2-dimensional projections of a subset of housekeeping genes ( Fig. 4A, left) and all genes (Fig. 4A, right) . Housekeeping genes showed less dispersal than all expressed genes in the spinal microglia (Fig. 4A) , suggesting that not all genes show a broad variation (see also Fig. S2C ; http://links.lww.com/PAIN/A204). The JSD index was used to numerically quantify the visual pattern ( Fig 4B) . As seen in Figure 4B for both sham and injury conditions, we observed a general increase in variability over time (Fig. S2A) . We additionally compared the ratio of variances of each gene (POD7/POD1 and shamPOD7/shamPOD1) by an F test. In the injury condition, a smaller number of genes increased in variation over time than in the sham condition (Fig. S2B) . We note that unlike tissue samples with millions of cells that might average across any hidden subtypes, our 10-cell sample collection might be disproportionately affected by hidden subtypes with the result that replicate samples cannot be guaranteed to match their cell collection. If some samples have hidden subtypes while others do not, it may affect estimates of variation. However, we also note that the same hidden subtype factor exists for all our treatment conditions and we are making inferences based on differential variation across the treatment conditions.
We hypothesized that the cells in an organismal environment show natural single-cell variability. When these cells are stressed or stimulated, such as by injury signals from primary afferent neurons, a subset of the transcriptome may respond with activation of specific pathways. We also hypothesized that such activation will have the effect of synchronizing or resetting the genes in those pathways to a coordinated expression pattern and thereby reduce variability across the samples for that subset of genes. In a temporal sequence, the transcriptome may show broad coordinated expression from the initial stress response to both injury and the collection protocol and then subsequently relax back to its natural heterogeneous state except for the specifically activated pathways. Therefore, we reasoned that key gene classes linked to the maintenance of neuropathic pain might be found among genes that show relatively low variation in the late phase of POD7. To explore this hypothesis, we first examined the patterns of time-dependent changes in cell-to-cell heterogeneity for a collection of 172 genes hypothesized to be important in pain categorized into 6 functional groups relevant to microglia activation 31 : cytoskeleton/ECM, enzyme, GPCR, receptor, secreted molecule, and transcription regulation (Table. S2 ; http:// links.lww.com/PAIN/A205). Among these, some categories such as GPCRs and transcription regulation showed decreased cellto-cell variation with time for the injury condition (Fig. S2C) . In particular, we saw a significantly lower variation in secreted molecules between POD1 and POD7 but not in the sham conditions (Fig. S2C) , which might be consistent with coordinated expression of pain maintenance factors because constant release of proinflammatory mediators contributes to central sensitization in spinal cord and chronic pain. 57 Given this observation, we conducted a screening strategy for the entire transcriptome to identify key genes by their pattern of temporal cell-to-cell variation. We examined the overlap of gene identities for the genes with time-dependent changes in their variation (Fig. 4C) and classified genes into 4 groups according to variation change of gene expression from day 1 to day 7: group A 5 estimated variation increased for both injury and sham, group B 5 estimated variation increased for injury but decreased for sham, group C 5 estimated variation decreased for injury but increased for sham, and group D 5 estimated variation decreased for both injury and sham. Among these groups, we expected group C genes to be the most plausible candidates for microglia activation and pain. We examined the clustering pattern of the samples using only the A, B, C, and D subset of genes by performing LDA projection (Fig. 4D) . In this figure, each dot is a 10-cell sample and the colors indicate the experimental treatments. Group C genes (56 genes; Table S3 ; http://links.lww.com/PAIN/A206) were particularly noticeable in inducing tight groupings of the 4 experimental conditions consistent with the idea that these genes were informative for distinguishing the microglia treatment states. Interestingly, group C contains P2ry12, which has been known to regulate microglia activation in neuropathic pain. 25, 53 These observations led us to functionally test genes selected from this group.
Validation of candidate pain genes
As mentioned above, we identified a gene set of interest using 2 different analytic approaches: DEGs and variation analysis. Among the POD1-specific DEGs, we focused on 3 miRNAs (miR-137, miR-29b-1, and miR-29c) because miRNAs are known to regulate transcription and have considerable effects on cellular functions. 50 Expression of miR-137 was increased at POD1, whereas expression of miR-29b-1 and miR-29c were significantly lower at POD1 (Fig. 5A) . We validated miR-29c expression using real-time PCR with ipsilateral spinal cord after L4 SNT (Fig. 5B) . Because P2X and P2Y signals are known to be important for pain hypersensitivity following peripheral nerve injury, 1, 34 we adopted in vitro ATP stimulation to activate microglia and assess the expression of these 3 miRNAs. Consistent with our 10-cell microarray data, real-time PCR showed significant downregulation of miR-29c (Fig. 5C ) and miR-29b-1, but no upregulation of miR-137 (data not shown), in ATP-stimulated microglia. Although miR-137 might still have expression changes, these results suggested a focus on miR-29b-1 and miR-29c as targets for in vivo functional assays. Activated microglial cells are known to increase the expression of proinflammatory cytokines, such as TNFa and Il-1b, and phosphorylated p38 MAP kinase (pp38). 29 We measured the expression of cytokines in miR-29c inhibitor-transfected microglia. MiR-29c inhibitor increased TNFa expression compared to inhibitor control group, whereas we found no difference in Il-1b mRNA expression in primary cultured microglia (Fig. 5C) . We also found a significant increase of pp38 expression in the miR-29c-inhibitor-transfected microglia (Fig. 5D) . Together, these results were consistent with the hypothesis that miR-29c downregulation recapitulates the cytokine responses found in activated microglia. We next examined physiological consequences of miR-29c downregulation in microglia. Application of miR-29c-inhibitor-transfected microglia elicited calcium responses in DRG neurons (Fig. 5E) . With ex vivo whole spinal cord preparation, we also found significant long-term potentiation (LTP) of evoked postsynaptic field potentials (fPSPs) in spinal dorsal horn following local application of miR-29C-inhibitor-transfected microglia (Fig. 5F ). Intrathecal application of activated microglia by ATP produces mechanical allodynia in rats. 54 To dissect their role in pain, we investigated whether miR-29c inhibitor-transfected microglia are sufficient to produce tactile allodynia when injected into naive animals. The paw withdrawal threshold decreased markedly in normal mice after the intrathecal injection of miR-29c-inhibitortransfected microglia, but not in the inhibitor control group (Fig.  5G) , suggesting that downregulation of microglial miR-29c in spinal cord is sufficient for developing mechanical allodynia. In addition, we tested whether miR-29c overexpressing microglia can resolve mechanical allodynia induced by ATP-stimulated microglia. Application of miR-29c-mimic-transfected microglia significantly reversed mechanical allodynia, compared to controlmiRNA-transfected microglia at 5 hours after injection; mice injected with control miRNA were comparable to mice injected with ATP-stimulated microglia (Fig. 5H) . Motor behavior, assessed by rotarod test, was not changed by microglial injection per se (data not shown). Collectively, these results suggest that downregulation of miR-29c in microglia may play an important role in the development of neuropathic pain.
Next, we focused on 56 genes found through temporal variation analysis (group C; see above) to assess whether any of these genes may play a role in the development/maintenance of neuropathic pain. Of the 56 identified genes, we used information from previous literature to focus on changes in the expression level of 9 genes (Hexb, Gria1, Glul, P2ry12, Trf, Spg21, Cdk5, Bank1, and Arf6) in the ipsilateral spinal cord at POD7. Of the 9 genes, only the P2ry12 expression showed a significant difference between that of sham and POD7, but we found no significant difference in other 8 genes ( Fig. S4A ; http://links.lww.com/PAIN/A208). Because microglial changes could be masked in the whole spinal cord tissue, we additionally tested expression changes under in vitro ATP stimulation conditions. Under ATP simulation, we only found a significant change in the expression of Gria1, the gene encoding AMPA receptor subunit GluA1, both at mRNA and protein levels (Figs.  6A, B) , but not for the other 8 genes (Fig. S4B ). An immunofluorescence analysis revealed that microglia stained with Iba-1 expressed GluA1 in the resting state, whereas its expression significantly decreased when microglia were treated with ATP (Fig. 6B) . A previous study suggested that activation of AMPA receptor by glutamate promotes release of TNFa whereas the potentiation of microglial AMPA receptors by AMPA receptors agonist inhibits TNFa release. 22 Microglial Gria1 knockdown induced TNFa release and increased mRNA expression (Figs.  6C, D) . We tested live animal response to Gria1 expression changes by intrathecal injection of siGria1 microglia. Similar to our results for miR-29c, we found that microglial Gria1 knockdown produced mechanical allodynia. Paw withdrawal threshold decreased only after the injection of siGria1 microglia, but not of siScram microglia (Fig. 6E) . With administration of etanercept (1 mg, i.p.), a TNFa inhibitor, 1 hour after injection of siGria1 microglia, siGria1 microglia induced pain was significantly reversed at 5 hour after microglial injection (Fig. 6F) . Taken together, these results suggest that Gria1 downregulation may contribute to mechanical allodynia through TNFa production.
Discussion
In this study, we adopted a high resolution, individually collected, transcriptome assay to screen for microglia-specific factors for the first time in a rodent neuropathic pain model. Mechanical collection of marked microglia allowed us to assess pure cell populations for expression changes resulting in an unbiased (up to probes on the microarray) discovery process. Furthermore, our approach allowed us to further examine the diversity of gene profiles within multiple small pools of cells coupled with a timedependent variation analysis resulting in a novel approach for candidate gene discovery. Many microglial changes could be masked in the analysis with the whole spinal cord tissue (Fig.  S4A) , and analyses based on cell variation would not have been possible with the whole tissue level data. From our analysis, we found downregulated miR-29c in early spinal microglia to be a possible factor for the microglia activation and the initiation or development of neuropathic pain and the possible role of Gria1 in time-dependent injury and pain response. The GO analysis further suggested that early and late microglia could have functionally distinct phenotypes following peripheral nerve injury although they are difficult to distinguish by morphology alone.
Validity of transcriptome analysis
Despite being obtained from a very small number of cells, the gene profile of previously known genes from this transcriptome data was largely consistent with general expectations from previous studies. Our 10-cell microglia data contained many spinal microglia-specific genes that were recently reported by Chiu et al. 9 We also minimized the possibility of contamination of infiltrating macrophage, given that brain microglia signature genes but not the peripheral monocyte signature genes were enriched in our microarray data. 5 Indeed, recent studies have suggested that infiltrating macrophages may not contribute to the neuropathic pain after peripheral nerve injury. 20 
Distinctive transcriptome profiles of early-phase and late-phase microglia
We found early microglia genes that are actively responding to peripheral nerve injury and leading to upregulation of receptors and channels at POD1 (and in some case at POD7 as well). Notably, in addition to TLR4 previously shown to be upregulated after nerve injury, 3 we also identified other toll-like receptors such as TLR7 and TLR13, which could be also important for the www.painjournalonline.com 973 microglia activation and neuropathic pain. Interestingly, a recent study showed that extracellular miRNAs can activate nociceptor neurons to elicit pain through TLR7. 45 It is also possible that extracellular miRNAs released from central primary afferents may activate microglia through TLR7. It has been reported that let-7b induces TNFa release from brain microglia through TLR7. 38 Furthermore, our transcriptome profiles revealed the distinctive difference in their functional phenotypes between the early-phase and late-phase microglia although they are difficult to be distinguished by morphology alone (Fig. 1B) .
Role of microglial miR-29c in initiation/development of neuropathic pain
We observed that downregulation of miR-29c might be involved in initial pain response. From in vitro studies with cytokine profiling and pp38 analysis, we verified that miR-29c inhibition recapitulates the profile of activated microglia and TNFa could be downstream in the pathway targeted by miR-29c. Behavioral studies revealed that downregulation of miR-29c in early spinal microglia after nerve injury modulates pain response, which may recapitulate initiation/development of neuropathic pain. Growing evidence indicates that miRNAs have a substantial role in modulating complicated pain pathways. 4, 40, 44, 45, 56 Furthermore, a recent study also demonstrated that the level of miR-29c is decreased in the serum of complex regional pain syndrome patients, 41 suggesting potential role of miR-29c in chronic pain. Given that Gria1 might not be a downstream target of miR-29c (Fig. S4D) , further work is required to identify target genes regulated by miR-29c and how those genes have a functional significance in the neuropathic pain conditions.
Individual heterogeneity of spinal microglia in transcriptome
Like individual cells found in other tissues, 37 spinal microglia displayed a substantial estimated individual variation in their transcriptome. Our measurement of variation is not as sensitive as single-cell measurements because of the pooling of the 10 cells. Under random sampling, the variance of the mean of the samples is expected to be proportional to the variance of the individual cells. Nevertheless, we note that pooled cell measurements are indirect estimates of individual variation. We hypothesized that individual microglia in their normal state might exhibit heterogeneous gene expression to dynamically reflect microenvironmental changes. However, external stimuli, such as skin lesions, may lead to transient coordinated expression of a subset of genes, which may later relax back into natural cell-to-cell heterogeneity. In the late phase of injury, under the continuous stimuli from injured nerves, a certain specific set of genes may remain coordinately expressed, leading to reduced variability in that gene set which are functionally associated with the pathophysiological neuropathic pain outcome. Thus, examination of single-cell level variability may be a powerful tool in identifying novel key genes under specific stimulus.
Role of microglial Gria1 in maintenance of neuropathic pain
Since some previous studies have mostly focused on the upregulated genes after nerve injury, 21 ,51 most of the 56 genes identified with variation analysis in this study were rarely detected from such whole tissue expression profiling. From these genes, we focused on Gria1 as a strong candidate gene for functional role and knockdown of microglial Gria1 produced mechanical allodynia in naive mice, which was reversed by TNFa inhibitor (Fig. 6F) . Previous studies demonstrated that expression of Gria1 is significantly decreased in activated brain microglia and unexpectedly, potentiating microglial AMPA receptors by AMPA receptor agonist inhibits TNFa release, whereas activation of AMPA receptor by glutamate promotes release of TNF by rat microglia. 22 In this study, we found that the downregulation of microglial GluR1 may lead to increased TNFa release 46 contributing to central sensitization in the spinal cord that might lead to the maintenance of neuropathic pain. It was found that both miR29c and Gria1 were also highly expressed in neurons in the spinal cord ( Fig. S3B ; http://links.lww.com/PAIN/A207) such that the strong signals from the neurons made it difficult to determine their levels in microglia. However, we believe this does not affect the hypothesis that miR-29c and Gria 1 are involved in microglial regulation as the functional role of the genes may be cell-type-specific. Indeed, it is notable that we clearly observed downregulation of miR-29c in the spinal dorsal horn after nerve injury (Fig. S3A ) and in the original transcriptome data.
In summary, this study demonstrates that transcriptome analysis with individual collections of spinal microglia can be a relevant tool to reveal a microglial gene-expression signature following peripheral nerve injury. This high-resolution analysis reveals significant differences in the gene profile between early (POD1) and late (POD7) microglia and it is likely that microglia exhibit functionally distinctive phenotypic changes over time following nerve injury. Of note, downregulation of miR-29c in early spinal microglia following peripheral nerve injury might be important for the initiation or development of neuropathic pain and Gria1 for the maintenance of neuropathic pain. Our work provides insight into spinal microglial biology and potential new microglial targets for the treatment of chronic pain such as neuropathic pain.
